Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

QQEW vs ABCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: QQEW 0 – 5 ABCL (1 Tie) Matrix Metrics: QQEW 1 – 9 ABCL

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). QQEW carries a Unified Composite Score of 58.9/100 (HOLD) at $145.79 (N/M Forward P/E, N/A operating margin), whereas ABCL carries 63.3/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin).

  • Technical & Structure Timing Caution: QQEW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QQEW vs ABCL
QQEW NASDAQ
First Trust NASDAQ-100 Equal Weighted Index Fund
Institutional Equity
$145.79
-2.13% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.33β · 34% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 39
RSI-14: 38.6 · SMA20: $151.66 · SMA50: $157.11
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
TTM Revenue $66M
Forward P/E 27.6x
Beta / 30D Vol 2.31β · 87% Vol
Unified Composite Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.3 · SMA20: $12.04 · SMA50: $12.33

6-Pillar Scorecard Institutional Category Breakdown (QQEW 0 – 5 ABCL)

Columns: Metric · QQEW · ABCL
1. Valuation Multiples ABCL
Forward P/E N/M 27.6x
Trailing P/E N/M 27.6x
PEG Ratio N/M N/M
EV / Revenue N/M 56.9x
2. Growth & Scale ABCL
Revenue Growth (YoY) N/A -76.3%
Earnings Growth (YoY) N/A +45.9%
TTM Revenue (USD) N/A $66M
Market Cap N/A $3.8B
3. Profitability & Quality ABCL
Gross Margin N/A N/A
Operating Margin N/A -1550.0%
Net Profit Margin N/A -248.8%
Return on Equity (ROE) N/A -17.3%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) N/A -$33M
Cash Flow Margin N/A -49.6%
Net Cash / Leverage N/A ROE $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABCL
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 19.8% (86th %ile) 80.8% (25th %ile)
Put/Call OI Skew N/A 0.23x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QQEW (1) vs ABCL (9)
Institutional Metric QQEW ABCL Criterion Row Edge
Market Capitalization
Scale
N/A $3.8B Larger Scale ABCL
Trailing P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY)
Growth
N/A -76.3% Higher Growth ABCL
Operating Margin (TTM)
Profitability
N/A -1550.0% Higher Margin ABCL
Net Profit Margin
Profitability
N/A -248.8% Higher Margin ABCL
Return on Equity (ROE)
Capital Efficiency
N/A -17.3% Higher ROE ABCL
52-Week Range Position
Momentum
52% ($122–$167) 69% ($3–$15) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
1.33β · 34% Vol 2.31β · 87% Vol Lower Realized Risk QQEW
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 63.3 / 100 (BUY) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
N/A $66M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 56.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$33M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABCL +0.52 pp
QQEW: -5.73% · ABCL: -5.21%
3M Horizon ABCL +11.43 pp
QQEW: -10.85% · ABCL: +0.58%
6M Horizon ABCL +168.27 pp
QQEW: +0.6% · ABCL: +168.87%
1Y Horizon ABCL +204.88 pp
QQEW: +4.1% · ABCL: +208.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QQEW vs ABCL. Trailing 12-month operating profitability (QQEW N/A vs ABCL -1550.0%) and valuation multiples (QQEW N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.

QQEW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$66M
Gross MarginN/A
Op. Margin-1550.0%
ROE / Fwd P/E-17.3% · 27.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QQEW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 19.8%
IV Percentile 86th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QQEW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABCL CONSOLIDATION
34d in phase · OBV NEUTRAL
Current IV 80.8%
IV Percentile 25th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QQEW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ QQEW vs ABCL Key Questions & Quantitative Answers

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). QQEW carries a Unified Composite Score of 58.9/100 (HOLD) at $145.79 (N/M Forward P/E, N/A operating margin), whereas ABCL carries 63.3/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin). Technical & Structure Timing Caution: QQEW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: QQEW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABCL at -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin). On trailing 12-month operating scale, QQEW generates N/A in USD-normalized revenue versus $66M for ABCL. In operating R&D and SG&A reinvestment, QQEW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.

ABCL screens cheaper on headline valuation multiples. QQEW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QQEW (N/A ROE) versus ABCL (-17.3% ROE) capital efficiency.

In options market volatility and institutional positioning, QQEW carries 19.8% implied volatility (86th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.33β · 34% Vol realized risk). By comparison, ABCL carries 80.8% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.31β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.